Passage Bio (PASG) - P/E multiplikatori
GURU.Markets platformasidagi ushbu narxlar grafigi Passage Bio, Inc. (PASG) faoliyatini aks ettiradi, bunda ko'rsatkich qiymati -0.30 darajasida turibdi. Biznes noyob bolalar miya patologiyalari uchun eksklyuziv davolash usullariga tayanadi, bu esa uning "orphan drug" (kam uchraydigan kasalliklar dori vositasi) maqomi tufayli barqaror daromadni ta'minlaydi. Biroq, mono-platforma strategiyasi yetkazib berish usullarining xavfsizligi bilan bog'liq binary xatarlarni yuzaga keltiradi. Ishlab chiqish jarayoni innovatsion viral vektorlardan foydalangan holda AQSh laboratoriyalarida olib borilmoqda.
Passage Bio Inc. (PASG) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil
- aksiya narxi va konsensus maqsadli narx:
- bozor kapitallashuvi ko'rsatkichlari:
- kompaniyaning balans qiymati tafsilotlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Umumiy qarzning kapitalga nisbati Passage Bio, Inc.|PASG - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli qarzdorlikning o'z kapitaliga nisbati Passage Bio Corp|PASG - Kompaniyaning jamlangan qarzlari|Balans qiymatiga qarzlar Passage Bio, Inc.|PASG - Kompaniyaning uzoq muddatli majburiyatlari|Kompaniyaning qisqa muddatli kredit va qarzlari Passage Bio|Tezkor likvidlik passagebio.com
- foyda va bozor multiplikatorlari tafsilotlari:
PASG - Sof foyda|Kompaniya foydasi prognozi Passage Bio, Inc.|PASG - Narxning foydaga nisbati|Prognoz qilingan narx-foyda nisbati Passage Bio Corp|PASG - Narx-foyda va o‘sish multiplikatori|Biznes qiymatining amortizatsiya chegirilishidan oldingi operatsion foydaga nisbati Passage Bio, Inc.|PASG - EBITDA operatsion foydasi|So'nggi to'rtta chorak uchun bir aksiya uchun sof foyda Passage Bio|PASG - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi 12 oy davomida bir aksiya uchun foydaning yillik o'sishi passagebio.com|PASG - Joriy yilda foyda o'sishi|Keyingi yil uchun bir aksiya uchun kutilayotgan foyda o'sishi Passage Bio, Inc.
Kompaniyaning jamlanma tahlili:PASG (passagebio.com)
P/E koeffitsiyenti aktivning haddan tashqari sotib olinganini yoki qadrsizlanganini baholash uchun aksiyaning bozor qiymatini biznesning sof foydasi bilan solishtirish orqali investitsiyalarning qoplanish muddatini belgilaydi. P/E baholash tendentsiyalarini tahlil qilish orqali investor kapitalning kamayish xavfini aniqlaydi, bu esa portfelni qisqartirish va M&A kelishuvlaridan voz kechganidan keyin asosiy CNS dori vositalarining organik rivojlanishi davrida Passage Bio, Inc. (PASG) uchun juda muhimdir.
Raqobatdosh kompaniyalar
biogen.com - Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori NBIX|P/E multiplikatori Regencell Bioscience Ltd (RGC)|Narxning foydaga nisbati Axsome Therapeutics Inc AXSM|Biznesning o‘zini qoplash muddati ACADIA Corp (ACAD)|XENE - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati vikingtherapeutics.com VKTX|SUPN: P/E multiplikatori|Catalyst Pharma (CPRX) - P/E multiplikatori|DNLI (Denali Therapeutics Inc) - P/E multiplikatori|HRMY - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|P/E multiplikatori BHVN|AMLX - Kapitalizatsiyaning foydaga nisbati|Trevi Therapeutics, Inc. - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati PRAX|Anavex Corp - P/E multiplikatori|CBLL: Narxning foydaga nisbati|PRTA: P/E multiplikatori|ALEC - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Annexon|Kapitalizatsiyaning foydaga nisbati Omeros Corp. OMER|Narx-foyda koeffitsiyenti NGNE (Neurogene Corp)|ACIU (AC Immune Inc) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori VYGR (Voyager Therapeutics)|Biznesning o‘zini qoplash muddati neumoratx.com (NMRA)|SCLX - Narxning foydaga nisbati|TVGN (Tevogen Bio Holdings Inc.) - Narx-foyda multiplikatori|ACOG: P/E multiplikatori|Narx-foyda koeffitsiyenti Cognition Therapeutics Inc.|Narx-foyda koeffitsiyenti IKT|cassavasciences.com (SAVA) - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Assertio Holdings, Inc. (ASRT)|COYA: Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori VTGN (Vistagen)|P/E multiplikatori Ovid Therapeutics Inc OVID|ABOS - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati cervomed.com CRVO|ATHE: P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Clene CLNN|Narxning foydaga nisbati PepGen Inc|Narx-foyda multiplikatori JUNS (Jupiter Neurosciences, Inc.)|P/E multiplikatori RLMD|ANVS - Kapitalizatsiyaning foydaga nisbati|Grace Therapeutics - Narx-foyda koeffitsiyenti|P/E multiplikatori Firefly Neuroscience, Inc. AIFF|KLTO - Narxning foydaga nisbati|Kompaniya qiymatining sof foydaga nisbati NRSN (NeuroSense Therapeutics)|Reviva Pharmaceuticals (RVPH) - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati MetaVia (MTVA)|Narxning foydaga nisbati NeurAxis|Helius Medical Technologies Inc. - Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori NEUP|P/E multiplikatori Minerva (NERV)|Narxning foydaga nisbati Athira Pharma, Inc. ATHA|Biznesning o‘zini qoplash muddati addextherapeutics.com (ADXN)|ALZN - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Cyclerion Therapeutics CYCN|PTIX: P/E multiplikatori|Pasithea Therapeutics Corp. (KTTA) - P/E multiplikatori|CRGT (Cortigent Inc) - P/E multiplikatori|ATXI - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|P/E multiplikatori BCLI|CARA - Kapitalizatsiyaning foydaga nisbati|Chromocell Therapeutics Corporation - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati ELYM|Intra-Cellular - P/E multiplikatori|LBPH: Narxning foydaga nisbati|MRNS: P/E multiplikatori|NKGN - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati NeuroBo|Kapitalizatsiyaning foydaga nisbati Sage Therapeutics Inc SAGE|Narx-foyda koeffitsiyenti SNPX (Synaptogenix, Inc.)|TRVN (trevena.com) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori VIGL (Vigil Neuroscience, Inc.)|Biznesning o‘zini qoplash muddati anewmeds.com (WENA)|CERE - Narxning foydaga nisbati
